ArticleFrontiers in aging neuroscience2026
Oxytocin reduces anger bias, harm-intention recognition, and self-focus in behavioral variant frontotemporal dementia: a randomized double-blind placebo-controlled crossover trial.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the effects of oxytocin administration on social cognition and social engagement in patients with behavioral variant frontotemporal dementia. Methods: In a within-subject, double-blind, placebo-controlled, randomized crossover trial, patients with behavioral variant frontotemporal dementia completed the primary outcome measures, facial emotion and intention recognition tasks. Secondary outcomes included evaluation of drug safety and tolerability and changes in social engagement, assessed through caregiver ratings of social behavior. Exploratory outcomes included anger-bias in emotion misclassification and a LIWC-based analysis of speech during a semi-structured interview. Results: Oxytocin was safe, well-tolerated, and improved social engagement in naturalistic contexts: caregivers reported positive changes, including increases in awareness, spontaneous initiative, socio-affective engagement, and reductions in appetite/impulsivity. Exploratory analyses suggested that oxytocin reduced the tendency to misclassify fearful and sad expressions as angry and reduced the use of first-person pronouns during spontaneous speech. However, the study detected no improvements in the emotion recognition and observed decreased accuracy in recognizing harmful intentions. Conclusion: Exploratory findings suggest that oxytocin reduces threat-bias, promotes social engagement, and decreases self-focused language, while no improvements were detected on experimental measures of social cognition. The results highlight the safety and potential of innovative oxytocin-based pharmacological interventions and the value of incorporating naturalistic assessments, such as ecological social interactions and language analysis, to optimize the detection of therapeutic effects in neurodegenerative diseases. Oxytocin may hold promise for enhancing social engagement in behavioral variant frontotemporal dementia, although its effects on language use and higher-order cognitive processes require further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.